Following on from the discussion about the US biosimilar landscape in the previous episode, CBPartners’ experts explore the trends and dynamics of the biosimilar market ex-USA – across the EU, Latin America and Asia Pacific regions, with a focu

Opportunities and Barriers for Biosimilar Uptake in the USA

May 20th, 2021 39m 3s

As the costs of biologic drugs increase, biosimilars have emerged as an appealing option for controlling costs and expanding access to treatment. While the uptake of biosimilars in the USA started off slowly, it has since gained a rapid pace.

USA Policy Expectations for a New Administration

Mar 5th, 2021 37m 51s

During the 2020 US Presidential Election, several campaign promises, policies, and healthcare reforms were presented by both the Republican and Democratic parties. Since winning the election, President Biden, his new administration, and the new

Digital Health (pt 3): Emergence of Companion Digital Treatments and Standalone Digital Therapeutics

Dec 4th, 2020 22m 53s

The rapid growth of digital therapeutics (DTx) in healthcare has seen the emergence of both companion digital treatments and standalone DTx in the market. The development and commercialization of standalone DTx in particular offers an interesti

Digital Health (pt 2): New Medical Technologies and Clinical Trials

Oct 6th, 2020 18m 35s

Digital health is set to transform the collection and sharing of data which could be used in the assessment of new medical technologies. The proliferation of digital health tools has helped to drive innovation in digital therapeutics, clinical

Digital Health (Pt 1): Current Landscape and Payer Dynamics

Aug 27th, 2020 16m 32s

The number of virtual medical consultations when compared to in-person consultations is growing dramatically year-on-year. As such, the ‘digital medicine’ trend is revolutionizing healthcare delivery as we know it – and the transition, partiall

Alzheimer's and Aducanumab: The Beta Amyloid Theory's Last Hope

Jul 21st, 2020 12m 14s

Despite $2.8 billion allocated by the NIH to Alzheimer's research in 2020 alone, results to date have been rocky. Why is this disease that affects millions of people so tough to crack? This episode of CBPartners’ podcast seeks to answer this qu

COVID-19 (Pt 3): Testing

May 26th, 2020 31m 7s

This final episode of the COVID-19 trilogy focuses on testing. Specifically, the different types of tests available for COVID-19 and the regulatory environment in which these tests exist. How will an accurate test change how healthcare experts

AMARIN's VASCEPA patent loss: is it obvious(ness)?

May 7th, 2020 11m 54s

Patent management is the hot topic of this episode. The focus is on AMARIN’s leading product, VASCEPA, a drug made up of natural derivatives such as fish oil and was approved by the FDA in December 2019.Healthcare consultant Jared Wolff is jo

COVID-19 (Pt 2): Promising Treatments in Development

Apr 21st, 2020 20m 44s

In Part 2 of the COVID-19 series, healthcare consultant Jared Wolff is again joined by Matthew Rube and Akhil Parlapalli from CBPartners’ New York office to discuss some of the most promising treatments that are currently being put to the test

Cell and Gene Therapy Roundtable

Mar 26th, 2020 17m 58s

In this episode, our host Jared Wolff is joined by healthcare consultants Sophie Katz (a core member of CBPartners' Cell and Gene Therapy Center of Excellence), and Jay Galli to discuss some interesting topics surrounding cell and gene therapie

COVID-19 (Pt 1): Roundtable

Mar 18th, 2020 22m 13s

DISCLAIMER: This episode was recorded on March 13th, 2020. All figures mentioned, such as the number of confirmed disease cases, were accurate at the time of recording.--In this episode, healthcare consultant Jared Wolff is joined by Matthe

Rate